Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471259 | 0.82 | CA12 (0.41) | ALDH1A1PKMALOX5MLYCD | |
| SCHEMBL24370474 | 0.81 | MAPT (0.35) | ALDH1A1PKMMLYCDHTR1AGAA | |
| SCHEMBL21789349 | 0.79 | ALOX5 (0.33) | ALDH1A1PKMALOX5MLYCD | |
| SCHEMBL3200366 | 0.78 | LMNA (0.42) | ALDH1A1MLYCDHTR1AGAAKDM4E | |
| SCHEMBL17472047 | 0.77 | ALDH1A1 (0.41) | ALDH1A1PKMALOX5MLYCD | |
| SCHEMBL21789494 | 0.77 | MLYCD (0.37) | ALDH1A1PKMALOX5MLYCD | |
| SCHEMBL3482612 | 0.76 | ALOX5 (0.39) | ALOX5SLC6A2SLC6A4 | |
| SCHEMBL8293473 | 0.75 | DPP4 (0.41) | ALDH1A1PKMALOX5KDM4ESLC6A2 | |
| SCHEMBL3483157 | 0.74 | ALOX5 (0.41) | ALOX5 | |
| SCHEMBL16160767 | 0.73 | ALOX5 (0.38) | ALOX5KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170857-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | ALDH1A1 1664/4885PKM 689/4885ALOX5 1164/4885 |
| US-10550071-B2 | PPAR agonists | PPARG, PPARD, PPARA | ALDH1A1 1664/4885PKM 689/4885ALOX5 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.